No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 4.2x · 10Y median 8.4x · 30th percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T11:55:37.749Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T11:55:37.749Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T11:55:37.749Z. Latest historical point 2026-03-31.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T11:55:37.749Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Alvotech (ALVO) stock was $6.11 as of Oct 5, 2026, 4:00 PM EDT, up 12.11% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -26.4% · 3-year avg -12.4%/yr
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer.
Drug Manufacturers - Specialty & Generic · Luxembourg, LU
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2023-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.03
Revenue Est.
$136.78M
Last Quarter Results
EPS
$-0.11
vs Estimate
$-0.08
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ALVO | $2.07B | $6.11 | +12.11% | -26.45% | N/A | N/A | N/A |
| 2BCRX | $2.06B | $8.10 | -0.86% | +13.22% | -10.02% | +5.82% | vs ALVO |
| 3INSP | $2.05B | $70.75 | +1.11% | -7.58% | -21.38% | N/A | vs ALVO |
| 4ADUS | $2.11B | $112.98 | +1.54% | +0.25% | +8.33% | +15.62% | vs ALVO |
| 5AUPH | $2.02B | $15.72 | -0.69% | +38.29% | -5.88% | +14.53% | vs ALVO |
| 6FTRE | $2.01B | $21.11 | +5.55% | +122.53% | N/A | N/A | vs ALVO |
N/A
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
$106.00M
vs Estimate
$103.00M
Consensus Rating
Based on 5 analysts
Average Price Target
$6.80
+11.3% upside
Low
$4.00
Current
$6.11
High
$9.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.04 | $-0.03 | $-0.01 | 2 |
| Quarter ending Dec 2026 | $0.15 | $0.17 | $0.18 | 2 |
| Quarter ending Mar 2027 | $0.01 | $0.01 | $0.01 | 1 |
| Quarter ending Jun 2027 | $0.01 | $0.01 | $0.01 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.05 | $-0.01 | $0.01 | 3 |
| FY 2027 | $0.17 | $0.23 | $0.28 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $132.67M | $136.78M | $140.88M | 1 |
| Quarter ending Dec 2026 | $250.37M | $250.98M | $251.58M | 1 |
| Quarter ending Mar 2027 | $170.83M | $171.04M | $171.25M | 1 |
| Quarter ending Jun 2027 | $175.80M | $176.02M | $176.23M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $621.03M | $626.46M | $631.89M | 4 |
| FY 2027 | $707.36M | $760.83M | $814.30M | 4 |
